FEMASYS INC — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Femasys completed a $30M private placement (with potential $90M from warrant exercise) in Q2 2026, restoring Nasdaq listing compliance. The company reported H1 2026 sales of $756.7K (up 0.8% YoY) but net loss of $3.6M ($1.08/share), improved from $10.5M loss ($7.76/share) in H1 2025, primarily due to $1.1M R&D reduction and $4.2M gain on warrant liability revaluation. Cash fell to $1.4M pre-financing; post-closing the company holds ~$30M to fund commercial expansion of FemaSeed and FemBloc clinical/regulatory programs.
Why this rating
$30M financing equals >100% of company market cap ($29.9M), extending runway materially and enabling commercialization. Nasdaq compliance restoration and warrant liability elimination eliminate delisting risk. However, Q2 sales declined 18.9% YoY, and path to profitability unclear.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.